Published On: Thu, Sep 14th, 2017

Should You Sell Advanced Accelerator Applications S.A. Based On Current Broker Views?


Recently stock market analysts have updated their consensus ratings on shares of Advanced Accelerator Applications S.A. (NASDAQ:AAAP).

The latest broker reports which have been released state 2 analysts have a rating of “buy”, 2 analysts “outperform”, 2 analysts “hold”, 0 analysts “underperform” and 0 analysts “sell”.

Most recent broker ratings

09/01/2017 – Advanced Accelerator Applications S.A. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 60 price target on the stock.

07/27/2017 – Advanced Accelerator Applications S.A. was upgraded to “mkt outperform” by analysts at JMP Securities. They now have a USD 69 price target on the stock.

06/15/2017 – JP Morgan began new coverage on Advanced Accelerator Applications S.A. giving the company a “overweight” rating. They now have a USD 50 price target on the stock.

11/29/2016 – Advanced Accelerator Applications S.A. was downgraded to “market perform” by analysts at Wells Fargo.

03/16/2016 – Advanced Accelerator Applications S.A. had its “neutral” rating reiterated by analysts at Citigroup. They now have a USD 36 price target on the stock.

12/07/2015 – Canaccord Genuity began new coverage on Advanced Accelerator Applications S.A. giving the company a “buy” rating. They now have a USD 35 price target on the stock.

Advanced Accelerator Applications S.A. has a 50 day moving average of 0.00 and a 200 day moving average of 0.00. It has a 52-week low of 23.50 and a 52-week high of 55.40.

The share price of the company (NASDAQ:AAAP) was up +3.98%, with a high of 55.40 during the day and the volume of Advanced Accelerator Applications S.A. shares traded was 236061.

Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. The Company has a portfolio of nine diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. Its commercial products include Gluscan/Gluscan 500/Barnascan, FluoroChol, MIBITEC/Adamibi, DOPAVIEW, Leukokit, Neurolite, SomaKit and NETSPOT. Additional MND product candidates include Annexin V-128, a SPECT product candidate for the imaging of apoptotic and necrotic lesions with potential applications in a range of indications.